Tumor response predictors in radioimmunotherapy of previously untreated non-Hodgkin's lymphoma (NHL) with Iodine I 131 tositumomab.

被引：0
|
作者：
Zasadny, KR
Rommelfanger, SG
Regan, DD
McCullough, NT
Kroll, S
Stagg, R
Kaminski, MS
Wahl, RL
机构：
[1] Univ Michigan, Ann Arbor, MI 48109 USA
[2] Coulter Pharmaceut Inc, S San Francisco, CA USA
来源：
JOURNAL OF NUCLEAR MEDICINE | 2000年 / 41卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
114
引用
收藏
页码：29P / 30P
页数：2
相关论文
共 50 条
  • [1] Dosimetry of iodine I 131 tositumomab in previously untreated patients with non-Hodgkin's lymphoma (NHL).
    Zasadny, KR
    Rommelfanger, SG
    Regan, DD
    McCullough, NT
    Kroll, S
    Kaminski, MS
    Wahl, RL
    JOURNAL OF NUCLEAR MEDICINE, 2000, 41 (05) : 82P - 83P
  • [2] Sequential administration of chemotherapy followed by radioimmunotherapy with Iodine-131-Tositumomab in untreated non-Hodgkin's lymphoma (NHL)
    Kostakoglu, L
    Goldsmith, SJ
    Vallabhajosula, S
    Coleman, M
    Morris, A
    Link, BK
    Kaminski, MS
    Nadeau, K
    Valente, N
    Leonard, JP
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (08): : 981 - 981
  • [3] Tositumomab and iodine I 131 tositumomab: Efficacy and safety in 141 patients (pts) with previously untreated low-grade (LG) non-Hodgkin's lymphoma (NHL).
    Kaminski, MS
    Coleman, M
    Link, BK
    Wahl, RL
    Goldsmith, SJ
    Kostakoglu, L
    Leonard, JP
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 575S - 575S
  • [4] Fludarabine monophosphate followed by iodine I 131 tositumomab for untreated low-grade and follicular non-Hodgkin's lymphoma (NHL).
    Leonard, JP
    Coleman, M
    Kostakoglu, L
    Chadburn, A
    Cesarman, E
    Bhatnagar, A
    Tidmarsh, GF
    Kroll, SM
    Goldsmith, SJ
    BLOOD, 1999, 94 (10) : 90A - 90A
  • [5] Update on the rational use of tositumomab and iodine-131 tositumomab radioimmunotherapy for the treatment of non-Hodgkin's lymphoma
    Burdick, Michael J.
    Macklis, Roger M.
    ONCOTARGETS AND THERAPY, 2009, 2 : 229 - 242
  • [6] Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement
    Mones, Jodi V.
    Coleman, Morton
    Kostakoglu, Lale
    Furman, Richard R.
    Chadburn, Amy
    Shore, Tsiporah B.
    Muss, Daniel
    Stewart, Patricia
    Kroll, Stewart
    Vallabhajosula, Shankar
    Goldsmith, Stanley J.
    Leonard, John P.
    LEUKEMIA & LYMPHOMA, 2007, 48 (02) : 342 - 348
  • [7] Phase II study of CVP followed by tositumomab and iodine I 131 tositumomab (Bexxar therapeutic regimen) in patients with untreated follicular non-Hodgkin's lymphoma (NHL).
    Link, B
    Kaminiski, MS
    Coleman, M
    Leonard, JP
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 562S - 562S
  • [8] Durable remissions from fludarabine followed by the iodine I-131 tositumomab Bexxar therapeutic regimen for patients with previously untreated follicular non-Hodgkin's lymphoma (NHL).
    Leonard, JP
    Coleman, M
    Kostakoglu, L
    Chadburn, A
    Fiore, JM
    Furman, RR
    Schuster, MW
    Kroll, SM
    Goldsmith, SJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 562S - 562S
  • [9] Single center experience with iodine I 131 tositumomab radioimmunotherapy for previously untreated follicular lymphoma (FL).
    Wahl, RL
    Zasadny, KR
    Estes, J
    Kison, PV
    Regan, DD
    McCullough, NT
    Kroll, S
    Stagg, B
    Kaminski, MS
    JOURNAL OF NUCLEAR MEDICINE, 2000, 41 (05) : 78P - 79P
  • [10] Radioimmunotherapy with tositumomab and iodine-131 tositumomab for low-grade non-hodgkin lymphoma: Nursing implications
    Estes, JM
    Clapp, KJ
    ONCOLOGY NURSING FORUM, 2004, 31 (06) : 1119 - 1126
12345